SCHEMBL1340064

SCHEMBL1340064

COc1ccc(-c2cc3c4cc(C(C)=O)ccc4n(C)c3n(C)c2=O)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ APAF1 O14727 1/20 0.41
▸ PABPC1 P11940 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ FASN P49327 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ CRHR1 P34998 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336873 0.87 GABRA1 (0.42) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL1339300 0.85 MAPT (0.45) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL1339301 0.85 MAPT (0.45) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL2385324 0.84 ALDH1A1 (0.47) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL1337357 0.82 ALDH1A1 (0.50) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL1339591 0.80 MAPT (0.42) MAPTALDH1A1TDP1RAB9AKDM4E
SCHEMBL2381071 0.80 KDM4E (0.44) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL3564916 0.79 MAPT (0.48) MAPTALDH1A1TDP1APAF1PABPC1
SCHEMBL1338688 0.79 GABRA1 (0.41) MAPTFASNKDM4E
SCHEMBL3572533 0.78 GABRA1 (0.38) ALDH1A1KDM4EHPGDHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 MAPT 2476/4885ALDH1A1 283/4885TDP1 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback